A few years ago, pioneering work revealed that the angiotensin II type 1 receptor antagonist, losartan, inhibited fibrosis in RDEB by effectively reducing TGF-β1 in cells in vitro, as well as TGF-β1 in circulation and in the skin of a RDEB mouse model [9]. This evidence concerns the gene AGTR1 and recessive dystrophic epidermolysis bullosa.